Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
Baxter Acquires AesRx For Sickle Cell Drug
by Lisa M. Jarvis
July 14, 2014
| A version of this story appeared in
Volume 92, Issue 28
Baxter has acquired AesRx, a Newton, Mass.-based biotech firm focused on orphan diseases. Baxter gains Aes-103, a small molecule that targets the underlying mechanism of sickle cell disease, a genetic blood disorder that affects roughly 100,000 people in the U.S. The deal marks the first acquisition of a drug candidate developed using resources from NIH’s National Center for Advancing Translational Sciences’ TRND program, which supports research on rare and neglected diseases. TRND and AesRx scientists jointly developed Aes-103 from preclinical studies through a successful Phase II trial.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X